← Leaderboards
Xin Xu
National Center For Advancing Translational Sciences
$0
Attributed
$0
Total exposure
0
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding mix
By agency
—
By mechanism
—
Top collaborators
No co-investigators on record.
Most similar at National Center For Advancing Translational Sciences
Same institution · by research overlap
Others in their field
Top investigators on “Drug Kinetics”
- Leonard Freedman · Leidos Biomedical Research, Inc.$241,865,009
- Sharon A Nachman · Johns Hopkins University$194,646,762
- Carol Nesel · Westat$147,274,423
- Barbara Driver · Westat, Inc.$103,746,400
- Ronald T Mitsuyasu · University Of California Los Angeles$99,239,507
- Lynn Briscoe · Leidos Biomedical Research, Inc.$93,714,869
Research focus
Drug KineticsResearch PersonnelPharmaceutical PreparationsDesignClinical TrialsCollaborationsLeadFormulationInvestigational DrugsToxic EffectAnimalsPropertyPre-ClinicalSafetyToxicologyPlaySmall MoleculeEvaluationPlasmaMetabolicMetabolismResourcesCellsRecombinants
Grant awards (27)
Pharmacokinetics and Drug Metabolism$4,779,148
ZIA · FY2025 · TR · contact PI
Pharmacokinetics and Drug Metabolism$5,131,109
ZIA · FY2024 · TR · contact PI
Pharmacokinetics and Drug Metabolism$5,444,464
ZIA · FY2023 · TR · contact PI
Pharmacokinetics and Drug Metabolism$1,703,261
ZIA · FY2022 · TR · contact PI
Pharmacokinetics and Drug Metabolism$1,889,528
ZIA · FY2021 · TR · contact PI
Pharmacokinetics and Drug Metabolism$3,645,996
ZIA · FY2020 · TR · contact PI
Pharmacokinetics and Drug Metabolism$2,410,920
ZIA · FY2019 · TR · contact PI
Pharmacokinetics and Drug Metabolism$2,286,500
ZIA · FY2018 · TR · contact PI
Evaluation of ACT1 to Treat Diabetic Keratopathy$505,302
ZIA · FY2017 · TR · contact PI
Development of an ApoA-1 Mimetic Peptide for Treatment of Atherosclerosis$449,192
ZIA · FY2017 · TR · contact PI
Peripheral CB1 Receptor Antagonist for Therapeutic Use in Metabolic Syndrome$442,958
ZIA · FY2017 · TR · contact PI
Metarrestin for the Treatment of Pancreatic Cancer$429,191
ZIA · FY2017 · TR · contact PI
Studies of Tumor-Penetrating Microparticles for Pancreatic Cancer Trauma$280,863
ZIA · FY2017 · TR · contact PI
Evaluation of ACT1 to Treat Diabetic Keratopathy$423,940
ZIA · FY2016 · TR · contact PI
Development of an ApoA-1 Mimetic Peptide for Treatment of Atherosclerosis$367,830
ZIA · FY2016 · TR · contact PI
Peripheral CB1 Receptor Antagonist for Therapeutic Use in Metabolic Syndrome$361,596
ZIA · FY2016 · TR · contact PI
Toxicity Studies of Nebulized Propofol Hemisuccinate$324,190
ZIA · FY2016 · TR · contact PI
Studies of Tumor-Penetrating Microparticles for Pancreatic Cancer Trauma$199,501
ZIA · FY2016 · TR · contact PI
Pre-Clinical Development of EDN-OL1 for Alzheimer's Disease$112,219
ZIA · FY2016 · TR · contact PI
Development of Minihepcidins for the Treatment of Beta Thalassemia$607,500
ZIA · FY2015 · TR · contact PI
Development of Exendin-(9-39) for the Treatment of Congenital Hyperinsulinism$269,000
ZIA · FY2015 · TR · contact PI
Evaluation of ACT1 to Treat Diabetic Keratopathy$253,333
ZIA · FY2015 · TR · contact PI
Toxicity Studies of Nebulized Propofol Hemisuccinate$225,500
ZIA · FY2015 · TR · contact PI
Development of an ApoA-1 Mimetic Peptide for Treatment of Atherosclerosis$219,667
ZIA · FY2015 · TR · contact PI
Peripheral CB1 Receptor Antagonist for Therapeutic Use in Metabolic Syndrome$212,500
ZIA · FY2015 · TR · contact PI
Studies of Tumor-Penetrating Microparticles for Pancreatic Cancer Trauma$132,125
ZIA · FY2015 · TR · contact PI
Pre-Clinical Development of EDN-OL1 for Alzheimers Disease$114,734
ZIA · FY2015 · TR · contact PI